Adiponectin plasma concentration, type 2 diabetes mellitus, cardiovascular diseases and features of metabolic syndrome
|
|
- Branden Kelley
- 6 years ago
- Views:
Transcription
1 Monika Żurawska-Kliś 1, Jacek Kasznicki 1, Marcin Kosmalski 1, Janusz Śmigielski 2, Józef Drzewoski 1 ORIGINAL 1 Department of Internal Medicine, Diabetology and Clinical Pharmacology, Medical University of Lodz, Poland 2 Department of Medical Informatics and Statistics, Medical University of Lodz, Poland Adiponectin plasma concentration, type 2 diabetes mellitus, cardiovascular diseases and features of metabolic syndrome Abstract Background. The aim of the study was to assess the relationship between adiponectin plasma concentration and anthropometric variables of obesity, type 2 diabetes mellitus (T2DM) as well as atherosclerotic-related cardiovascular diseases (CVD). Material and methods. 96 randomly selected subjects participated in the study, including 64 T2DM patients (aged ± ± 13.5 years; 34 women and 30 men; mean HbA 1c 7.9 ± ± 1.6%) and 32 without T2DM (aged ± years; 18 women and 14 men). Of 96 subjects, 37 diabetic patients and 19 non-diabetic subjects had documented CVD, defined as coronary heart disease, stroke or peripheral artery disease. Body mass index (BMI), waist circumference, waist to hip ratio (WHR) and blood pressure were determined. Plasma concentrations of adiponectin, glucose, insulin, total cholesterol and triglycerides were measured at fasting. Results. Circulating adiponectin level was significantly lower in T2DM patients than in non-diabetic subjects (7.26 ± ± 4.42 mg/ml vs ± 5.90 mg/ml; P < 0.001). Significant inverse correlations between adiponectin circulating level and WHR (r = 0.31; P < 0.05), total cholesterol (r = 0.26; P < 0.05), triglycerides (r = 0.35; P < 0.001) and HbA 1c (r = 0.25; P < 0.05) were found in T2DM patients. In subjects without diabetes the correlation was found only between adiponectin and triglycerides levels (r = 0.40; P < 0.05). Adiponectin plasma concentration did not differ depending on the presence or absence of CVD neither in diabetic nor in non-diabetic subjects. Conclusions. Adiponectin level in T2DM patients correlated negatively with WHR, total cholesterol, triglycerides and HbA 1c levels. No significant correlation between adiponectin level and atherosclerotic-related cardiovascular diseases was found both in T2DM patients and subjects without diabetes. Diabet Dośw Klin 2009; 9, 2: key words: adiponectin, obesity, type 2 diabetes mellitus, cardiovascular diseases Introduction Adiponectin is of particular interest in cardiometabolic diseases because of its close associations with insulin sensitivity and obesity. Plasma levels of adiponectin correlate inversely with glucose and insulin concentration, insulin resistance and HbA 1c [1, 2]. Several clinical studies have shown that adiponectin concentration is lower in obese and type 2 diabetic subjects [3 5]. Plasma concentrations of adiponectin are inversely associated with Address for correspondence: Józef Drzewoski, MD, PhD Klinika Chorób Wewnetrznych z Oddzialem Diabetologii i Farmakologii Klinicznej Uniwersytet Medyczny w Łodzi ul. Parzeczewska 35, Zgierz Tel (+48 42) , Fax (+48 42) jdrzew@poczta.onet.pl; jkasznicki@vp.pl Diabetologia Doświadczalna i Kliniczna 2009, 9, 2, Copyright 2009 Via Medica, ISSN markers of inflammation such as fibrinogen and C-reactive protein [6]. It was also reported that adiponectin attenuates leucocytes adhesion to endothelial cells via inhibition of adhesion molecules expression [7]. Adiponectin inhibits macrophage transformation to foam cells as well as their phagocytic activity [8, 9]. In addition, adiponectin diminishes oxidized low density lipoproteins accumulation in blood vessel wall and increases nitric oxide production in endothelial cells [10]. It is suggested that adiponectin via the above mentioned mechanisms may not only protect against atherosclerosis but also retard its progression [11, 12]. However, it is worth stressing that the results of some studies did not confirm significant link between adiponectin and cardiovascular disease [13 15]. The aim of our study was to assess the correlation of adiponectin plasma concentration and anthropometric variables of obesity, type 2 diabetes mellitus (T2DM) as well as atherosclerotic-related cardiovascular diseases (CVD) in T2DM subjects and in non-diabetic subjects. 81
2 Diabetologia Doświadczalna i Kliniczna 2009, Vol. 9, No. 2 Material and methods Patient selection The study population consisted of 96 randomly selected patients recruited from the Department of Internal Medicine, Diabetology and Clinical Pharmacology and from diabetic outpatient medical clinic between September 2003 and December Sixty four patients (aged ± 13.5 years; 34 women and 30 men; mean HbA 1c 7.9 ± 1.6%) were diagnosed with type 2 diabetes before the study entry. Thirty two subject (aged ± ± years; 18 women and 14 men) were diabetes free. Fasting serum glucose levels and 2 h after an oral glucose load were used to classify subjects according to the 1999 World Health Organization criteria into normal glucose metabolism. The patients were assigned into two subgroups: with or without cardiovascular disease (coronary artery disease, stroke and/or peripheral artery disease) confirmed by reviewing their medical records. All patients with type 2 diabetes were treated with diet, oral hypoglycemic agents (sulphonylureas and/or metformin), and/or insulin. The patients diagnosed with CVD were treated with appropriate medications, including angiotensin-converting enzyme inhibitors, beta- -blockers, calcium channel blockers, angiotensin receptor blockers, anti-platelet agents, lipid lowering agents and nitroglycerine. All participants received a complete physical examination including systolic and diastolic blood pressure, body weight, height, waist-to-hip ratio measurements, and evaluation of clinical signs of cardiovascular disease. Stature was measured to 0.5 cm on a stadiometer, and weight was measured to 0.1 kg on a balance scale. The waist circumference of each subject was measured at the level of umbilicus to the nearest millimeter with a fiberglass tape measure. Patients were not included if they suffered from any acute infections or chronic inflammatory processes, severe renal and liver dysfunction, autoimmune diseases or cancer. The study protocol was approved by the local ethics committee. Written informed consent was obtained from all patients before entering the study. Blood sampling Blood was sampled at fasting for the measurement of plasma glucose (FPG), plasma insulin, HbA 1c, total cholesterol, triglycerides and adiponectin concentration. ELISA (enzyme-linked immunosorbent assay) kits were used for the measurements of adiponectin and insulin plasma levels. Plasma glucose and lipids were assayed by routine automated laboratory methods. Total adiponectin was measured by Quantikine Human Adiponectin/Acrp30 Immunoassay, RáD Systems, UK (Catalog Number DRP300RaD) with an inter-assay coefficient of variation (CV) between 5.8% and 6.9%, and intra-assay CV of %. Insulin plasma levels were measured using INS-EASIA Assay, Biosource, Belgium (Catalog Number KAP1251) with an inter- and intra-assay CV between 4.5 and 9.5%, and 3.0 and 5.3%, respectively. Adiponectin and insulin concentrations were measured in plasma specimens that had been frozen at 20 o C and stored for no longer than 6 months. The following variables were also determined: body mass index BMI [(body weight)/(height) 2 ], waist circumference, waist to hip ratio WHR [(waist)/(hip)] and systolic and diastolic blood pressure. The insulin resistance index was calculated based on homeostasis model assessment (HOMA-IR) [16]. Statistical analysis Results are shown as means ± SD. Because of the skewness of the distributions U Mann-Withney s test was used to assess the differences between variables. Univariate associations of adiponectin with measures of adiposity, insulin, glucose, insulin resistance, lipids and blood pressure were determined using Spearman s rang correlation analysis. c 2 test was used to evaluate the relationships for non-continuous variables [17]. P values < 0.05 were considered statistically significant. Results The number of subjects in each group is given in Table 1, along with baseline demographic and descriptive characteristic. Type 2 diabetes mellitus patients exhibited significantly higher waist circumference, WHR and BMI compared with non-diabetic subjects. Fasting plasma glucose was also significantly higher in diabetic patients. There were no significant differences between those two groups in regard to the following variables: age, sex, systolic and diastolic blood pressure, fasting insulin level, total cholesterol and triglyceride concentrations, HOMA-IR. Significantly higher levels of total adiponectin were found in women compared to men (10.5 ± 6.21 mg/ml vs ± 5.04 mg/ml; P < 0.05; data not shown). Of the participants, 37 diabetic patients and 19 nondiabetics presented with CVD defined as coronary heart disease, stroke and/or peripheral artery disease (data not shown). In order to compare the relationship of adiponectin with diabetes mellitus and CVD we evaluated adiponectin plasma concentrations depending on the presence of diabetes mellitus, as well as CVD. The data are shown in Tables 2 and 3, and Figures 1 and
3 Monika Żurawska-Kliś et al., Adiponectin plasma concentration, type 2 diabetes mellitus Table 1. Characteristic of studied populations T2DM Non-T2DM P N Women/men 34/30 18/14 NS Age (years) ± ± NS Body mass index [kg/m 2 ] ± ± 4.95 < 0.05 Waist circumference [cm] ± ± 11.9 < Waist to hip ratio 0.95 ± ± 0.07 < 0.05 Systolic blood pressure [mm Hg] ± ± 13.2 NS Diastolic blood pressure [mm Hg] ± ± NS Fasting glucose [mmol/l] 7.8 ± ± 0.4 < Fasting insulin [miu/ml] 11.6 ± ± 9.64 NS HOMA-IR [U] 3.73 ± ± 2.13 NS Total cholesterol [mmol/l] 5.4 ± ± 0.9 NS Triglycerides [mmol/l] 1.9 ± ± 0.9 NS Data are shown as mean ± SD, T2DM type 2 diabetic subjects, non-t2dm non-diabetic subjects, N number of patients, NS not statistically significant Table 2. Adiponectin plasma concentration depending on the presence of type 2 diabetes mellitus Group of patients Adiponectin concentration [mg/ml] T2DM (+) (n = 64) 7.26 ± 4.42 T2DM ( ) (n = 32) ± 5.90 T2DM (+) diabetic subjects, T2DM ( ) non-diabetic subjects Table 3. Adiponectin plasma concentration depending on the presence of cardiovascular disease (CVD) Group of patients Adiponectin concentration [mg/ml] Figure 1. Adiponectin plasma concentration in diabetics [DM (+)] vs. non-diabetics [DM ( )] CVD (+) (n = 56) 9.81±5.43 CVD ( ) (n = 40) 8.88±6.33 CVD (+) patients with CVD, CVD ( ) patients without CVD As mentioned, there was a significant difference in adiponectin plasma level between type 2 diabetic patients and the subjects without diabetes (P < 0.001). On the contrary, adiponectin plasma levels did not differ according to presence or absence of CVD. The entire group of the patients enrolled in our study was also subdivided into four groups: 1. healthy subjects [T2DM( ),CVD( )]; 2. patients suffering from CVD only [T2DM( ), CVD(+)]; 3. type 2 diabetic subjects without CVD [T2DM(+), CVD( )]; 4. subjects suffering from both T2DM and CVD [T2DM(+),CVD(+)]. Figure 2. Adiponectin plasma concentration in subjects suffering from cardiovascular disease [CVD (+)] vs. subjects without cardiovascular disease [CVD ( )] 83
4 Diabetologia Doświadczalna i Kliniczna 2009, Vol. 9, No. 2 Table 4. Adiponectin plasma concentrations depending on the presence or absence of type 2 diabetes mellitus (T2DM) together with cardiovascular disease (CVD) Group of patients Adiponectin concentration [mg/ml] 1. T2DM ( ) CVD ( ) (n = 13) 14.5 ± T2DM ( ) CVD (+) (n = 19) ± T2DM (+) CVD ( ) (n = 27) 6.38 ± T2DM (+) CVD (+) (n = 37) 7.93 ± 4.85 We found significant differences of adiponectin plasma concentrations comparing the group of healthy subjects (group 1) with the group 3 (P < 0.001) and the group 4 (P < 0.01), as well as comparing the group 2 with the group 3 (P <0.001) and the group 4 (P < 0.001). The presence of CVD did not influence adiponectin plasma level neither in diabetic nor in non-diabetic subjects as there were no significant differences of adiponectin level between the group 1 and 2 as well as between the group 3 and 4. Spearman s rang correlation revealed significant inverse correlations between adiponectin plasma level and WHR (r = 0.31; P <0.05), total cholesterol (r = 0.26; P < 0.05), triglycerides (r = 0.35; P < 0.001) and HbA 1c (r = 0.25; P < 0.05) in T2DM patients. The only correlation in the control group was found between adiponectin and triglycerides (r = 0.40; P < 0.05). Discussion Figure 3. Distribution of adiponectin plasma concentration in subjects with and without diabetes depending on the presence of cardiovascular disease Figure 4. Distribution of adiponectin plasma concentration in subjects with and without cardiovascular disease depending on the presence of diabetes Adiponectin plasma concentrations in each group are shown in Table 4 and Figures 3 and 4. Adiponectin level has been reported to be significantly lower in diabetic compared to nondiabetic subjects [3]. The results of the present study and our previous work confirm these observations [5]. We also confirmed that serum adiponectin levels were significantly higher in diabetic women than in man, suggesting that at least some adiponectin concentration variability is sex related [18]. Interestingly, the difference between diabetic and non-diabetic subjects remains statistically significant regardless of the presence or absence of CVD. It was demonstrated between type 2 diabetic patients with CVD and non-diabetic patients (with and without CVD), as well as between type 2 diabetic patients without CVD and non-diabetic patients (with and without CVD). Adiponectin concentration in both groups of the patients did not differ according to the presence or absence of CVD. Moreover, we did not find statistically significant difference neither between type 2 diabetic patients with and without CVD, nor between non-diabetics with and without CVD. These data may suggest that the presence of CVD does not significantly influence adiponectin plasma concentration. On the contrary, Kumada et al. [19] reported significantly lower adiponectin concentrations in patients with coronary artery disease (CAD) compared to control subjects. Hotta et al. [20] found that plasma levels of adiponectin in diabetic individuals with CAD were lower than in diabetic patients without CAD. Observations made by Cavusoglu et al. [21] revealed that adiponectin plasma concentration was an independent predictor of myocardial infarction, cardiac mortality and all-cause mortality in a 2-year follow-up study. Pischon et al. [22] showed that high plasma adiponectin concentrations were associated with lower risk of MI in men. Otsuka et al. [23] found that non- 84
5 Monika Żurawska-Kliś et al., Adiponectin plasma concentration, type 2 diabetes mellitus -diabetic patients with CAD (n = 122) presented with lower adiponectin levels compared to those without CAD and multiple logistic regression analysis demonstrated that adiponectin independently correlated with the presence of CAD. However, it should be pointed out that we included in our study the patients not only with coronary heart disease but also with stroke and/or peripheral artery disease. Therefore, one can speculate that the patient population and inclusion criteria might have an impact on the results obtained in different centers. Shimada et al. [24] reported no predictive value of adiponectin for restenosis after elective coronary stenting. Similarly, Kuller et al. [14] did not show any relationship of adiponectin level with the risk of death from coronary heart disease. Nakamura et al. [15] noted significantly lower adiponectin plasma levels in patients with acute myocardial infarction and unstable angina pectoris but not with stable angina pectoris, compared to the control group. Zoccali et al. [25] observed that adiponectin levels were reduced in individuals with CVD, independently of obesity and diabetes. On the other hand, the data of Dunajska et al. [13] showed that men with coronary atherosclerosis had lower plasma adiponectin level than control subjects (16.2 ± 9.2 vs ± 6.7 mg/ml; P < 0.05). However, after including BMI and waist circumference as covariate data, the difference in adiponectin levels between men with CAD and control subjects lost statistical significance. Differences in the results between these studies may reflect underlying differences in the study populations. Serum concentration of total adiponectin is reduced in obese subjects. Several reports have suggested that reduction in plasma adiponectin level may be related to the elevation of insulin resistance [26]. However, data concerning the association between adiponectin and insulin resistance have been controversial. The inverse correlation was reported both in animals and humans [4]. On the other hand, observations made by other authors remain in contrast with these results [1]. Available data indicate also a negative relationship between plasma adiponectin level and fasting insulin level [3]. These observations were however not confirmed by other investigators [27, 28]. Similarly, the results of our study did not show any correlation between adiponectin plasma concentration, insulin and HOMA-IR. Some authors demonstrate the negative correlation between plasma adiponectin concentration and blood glucose level as well as HbA 1c [1, 2], however this was not confirmed by all authors [27, 29]. We partially confirmed the above relationships, as we have found a significant inverse correlation between adiponectin level and HbA 1c. Our results support the hypothesis that the relationship between adiponectin and insulin resistance may be more complex than initially thought. There are reports providing some indication that adiponectin levels can also be disassociated from insulin resistance. Abbasi et al. [30] pointed out that the relationship between adiponectin and insulin resistance is probably not one of direct cause and effect in all instances. They suggest that it is possible that in some situations their relationship may be mediated in part by insulin levels, by other hormones such as catecholamines or androgens, proinflammatory cytokines, medications, or possibly by changes in adiponectin clearance [30]. The data reveal the negative correlation between adiponectin plasma concentration and waist circumference, BMI and WHR, although some authors do not confirm these observations. The results concerning relationship of adiponectin level with blood pressure are also controversial [31]. In fact, we also noted the negative relationship between plasma adiponectin level and WHR, but not with waist circumference, BMI or blood pressure. Moreover, this correlation was revealed only in diabetic patients and was not shown in subjects without diabetes. The relationship between adiponectin and WHR in diabetic patients seems to be extremely relevant as this index estimates fat tissue distribution and is a measure of abdominal adiposity. Moreover, many authors suggest that WHR or waist circumference is much better and more precise measure of abdominal adiposity than BMI. This correlation seems to be relevant in the light of increasing prevalence of adiposity-related diseases. Recent clinical trials reveal negative relationship between adiponectin and total cholesterol and triglycerides [3, 4]. In our study, the significant correlation between adiponectin and total cholesterol was found only in type 2 diabetic patients. Relationship between adiponectin and triglycerides levels was demonstrated both in diabetics and subjects without diabetes. Limitations of the study The main limitation of our study is the relatively small sample size, which may have led to unstable estimates and a lack of power to detect significant associations. Another limitation of the present work is the fact that the actual adiponectin concentration depends on many endogenic and egzogenic factors, including age, gender, smoking and alcohol consumption [18, 32]. It has been recognized that some medications used by our patients could have potential impact on adiponectin plasma concentration. Numerous studies demonstrated that adiponectin levels are increased by various agents including thiazolidinediones. sulphonylureas, beta blockers, sartans and statins [33, 34]. It was also demonstrated that adiponectin levels correlate with renal function [35]. However, we would like to emphasize that it is very difficult, if not impossible, to recruit the patients not taking drugs that may influence adiponectin level. 85
6 Diabetologia Doświadczalna i Kliniczna 2009, Vol. 9, No. 2 Another limitation is the possibility of selection bias or ascertainment bias. Only subjects presenting with symptoms suggestive of CVD reported in their medical report were reported as having CVD. It is therefore possible that some CVD-affected patients buried among those classified as non-cvd. This may reduce the difference between the groups. The majority of studies concerning this issue were considering only coronary artery disease, and did not take into account the coexisting macrovascular abnormalities including stroke or peripheral artery disease. It seems also relevant that total adiponectin level and not high-molecular weight (HMW) adiponectin isoform was measured in our study. The result of some studies indicate that HMW adiponectin isoform appears to distinguish better the differences between certain groups of patients than assays for total adiponectin [36]. On the other hand, findings of Blüher et al. [37] did not support the superiority of HMW over total adiponectin in assessing metabolic variables such as insulin resistance or lipid profile. Adiponectin level correlates also with measures of obesity as well as glucose and lipids concentrations. Therefore, we suggest that adiponectin plasma level should be used as a potential marker of insulin-resistance related diseases, including type 2 diabetes mellitus and cardiovascular disorders, not solely but only when combined with other markers of cardiometabolic diseases such as measures of obesity, lipid and glucose concentrations, and others. Conclusions In summary, the results of the present study confirm that adiponectin plasma concentrations are significantly lower in type 2 diabetic subjects. In addition, its level correlates inversely with WHR, total cholesterol, triglycerides and HbA 1c. Our findings suggest that the link between adiponectin plasma concentration and type 2 diabetes mellitus is much stronger than between adiponectin level and cardiovascular diseases. However, to clarify the relationship of adiponectin with adiposity-related disorders further longitudinal and prospective studies are needed. This study was supported by grant number and from Medical University of Lodz, Poland. References 1. Heliovaara MK, Strandberg TE, Karonen SL, Ebeling P. Association of serum adiponectin concentration to lipid and glucose metabolism in healthy humans. Horm Metab Res 2006; 38: Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: Esposito K, Pontillo A, Di Palo C. et al. Effect of weight loss and life style changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289: Hanley A, Connelly P, Harris S, Zinman B. Adiponectin in a native Canadian population experiencing rapid epidemiological transition. Diabetes Care 2003; 26: Zurawska-Klis M, Drzewoski J. Inflammatory markers and adiponectin plasma level in patients with type 2 diabetes. Pol Arch Med Wew 2005; 114: Choi KM, Ryu OH, Lee KW. et al. Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract 2007; 75: Ouchi N, Kihara S, Arita Y. et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: Ouchi N, Kihara S, Arita Y. et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: Yokota T, Oritani K, Takahashi I. et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96: Hattori Y, Suzuki M, Hattori S, Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 2003; 46: Matsuda M, Shimomura I, Sata M. et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipovascular axis. J Biol Chem 2002; 277: Okamoto Y, Kihara S, Ouchi N. et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: Dunajska K, Milewicz A, Jedrzejuk D. et al. Plasma adiponectin concentration in relation to severity of coronary atherosclerosis and cardiovascular risk factors in middle-aged men. Endocrine 2004; 25: Kuller LH, Grandits G, Cohen JD Neaton JD, Prineas R. Multiple Risk Factor Intervention Trial Research Group. Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. Atherosclerosis 2007; 195: Nakamura Y, Shimada K, Fukuda D. et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 2004; 90: Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: Domanski C. Statistical tests. PWE, Warszawa Cnop M, Havel PJ, Utzschneider KM. et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46: Kumada M, Kihara S, Sumitsuji S. et al. Osaka CAD Study Group. Coronary artery disease: association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: Hotta K, Funahashi T, Arita Y. et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20:
7 Monika Żurawska-Kliś et al., Adiponectin plasma concentration, type 2 diabetes mellitus 21. Cavusoglu E, Ruwende C, Chopra V. et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 2006; 27: Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: Otsuka F, Sugiyama S, Kojima S. et al. Hypoadiponectinemia is associated with impaired glucose tolerance and coronary artery disease in non-diabetic men. Circulation J 2007; 71: Shimada K, Miyauchi K, Mokuno H. et al. Predictive value of the adipocyte-derived plasma protein adiponectin for restenosis after elective coronary stenting. Jpn Heart J 2002; 43: Zoccali C, Mallamaci F, Tripepi G. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end- -stage renal disease. J Am Soc Nephrol 2002; 13: Yamauchi T, Kamon J, Waki H. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: Krakoff J, Funahashi T, Stehouwer CD. et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003; 26: Kleiblova P, Springer D, Haluzik M. The influence of hormonal changes during menstrual cycle on serum adiponectin concentrations in healthy women. Physiol Res 2006; 55: Mannucci E, Ognibene A, Cremasco F. et al. Plasma adiponectin and hyperglycaemia in diabetic patients. Clin Chem Lab Med 2003; 41: Abbasi F, Chu JW, Lamendola C. et al. Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes 2004; 53: Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003; 16: Abbasi F, Farin HM, Lamendola C. et al. The relationship between plasma adiponectin concentration and insulin resistance is altered in smokers. J Clin Endocrinol Metab 2006; 91: Chu CS, Lee KT, Lee MY. et al. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 2006; 97: Drzewoski J, Zurawska-Klis M. Effect of gliclazide modified release on adiponectin, interleukin-6, and tumor necrosis factor-alpha plasma levels in individuals with type 2 diabetes mellitus. Curr Med Res Opin 2006; 22: Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005; 20: Sinha MK, Songer T, Xiao Q. et al. Analytical validation and biological evaluation of a high molecular-weight adiponectin ELISA. Clin Chem 2007 (published online 19 October 2007). 37. Blüher M, Brennan AM, Kelesidis T. et al. Total and high- -molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care 2007; 30:
ATHEROSCLEROTIC cardiovascular complications are the leading cause of. Diabetes Mellitus Has an Additional Effect on Coronary Artery Disease
Diabetes Mellitus Has an Additional Effect on Coronary Artery Disease To Decrease Plasma Adiponectin Levels Kuei-Chuan CHAN, 1 MD, Hsi-Hsien CHOU, 1 PhD, Der-Jinn WU, 1 PhD, Yi-Liang WU, 1 MD, and Chien-Ning
More informationA diponectin is a collagen-like plasma protein produced
528 CARDIOVASCULAR MEDICINE Implications of plasma concentrations of adiponectin in patients with coronary artery disease Y Nakamura, K Shimada, D Fukuda, Y Shimada, S Ehara, M Hirose, T Kataoka, K Kamimori,
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationAssociations among Lifestyle Status, Serum Adiponectin Level and Insulin Resistance
ORIGINAL ARTICLE Associations among Lifestyle Status, Serum Adiponectin Level and Insulin Resistance Hirokazu YOKOYAMA, Hiroshi HIROSE, Hideki OHGO* and Ikuo SAITO Abstract Objective The aim of this study
More informationChanges and clinical significance of serum vaspin levels in patients with type 2 diabetes
Changes and clinical significance of serum vaspin levels in patients with type 2 diabetes L. Yang*, S.J. Chen*, G.Y. Yuan, D. Wang and J.J. Chen Department of Endocrinology, Affiliated Hospital of Jiangsu
More informationType 2 diabetes mellitus is associated with lower serum adiponectin level in Bangladeshi population Abstract
16 Mediscope 2015;2(2):16-21 www.gmc.edu.bd ISSN: 2307-7689 Mediscope The Journal of GMC ORIGINAL ARTICLE Type 2 diabetes mellitus is associated with lower serum adiponectin level in Bangladeshi population
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationEffect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin
Metabolism Clinical and Experimental 55 (2006) 996 1001 www.elsevier.com/locate/metabol Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationRisk Factors for Heart Disease
Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress
More informationAssociation of Insulin Resistance and Selected Adipokines in Cardiovascular Disease with and without Metabolic Syndrome
JMSCR Volume 2 Issue Pages 11-11 May www.jmscr.igmpublication.org Impact Factor-1.114 ISSN (e)-234-1x Association of Insulin Resistance and Selected Adipokines in Cardiovascular Disease with and without
More informationFat Accumulation and Obesity-related Cardiovascular Risk Factors in Middle-aged Japanese Men and Women
ORIGINAL ARTICLE Fat Accumulation and Obesity-related Cardiovascular Risk Factors in Middle-aged Japanese Men and Women Miwa Ryo 1, Tohru Funahashi 1, Tadashi Nakamura 1, Shinji Kihara 1, Kazuaki Kotani
More informationDecrease in Plasma Adiponectin Concentrations in Patients With Variant Angina Pectoris
Circ J 2006; 70: 414 418 Decrease in Plasma Adiponectin Concentrations in Patients With Variant Angina Pectoris Soon Jun Hong, MD; Hong Seog Seo, MD; Seung Woon Rha, MD; Dong Joo Oh, MD; Jung Ah Kwon,
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationResearch Article Comparison of Different Anthropometric Measurements and Inflammatory Biomarkers
International Inflammation Volume 2012, Article ID 124693, 5 pages doi:10.1155/2012/124693 Research Article Comparison of Different Anthropometric Measurements and Inflammatory Biomarkers Yaron Arbel,
More informationMETABOLIC SYNDROME IN REPRODUCTIVE FEMALES
METABOLIC SYNDROME IN REPRODUCTIVE FEMALES John J. Orris, D.O., M.B.A Division Head, Reproductive Endocrinology & Infertility, Main Line Health System Associate Professor, Drexel University College of
More informationThe metabolic syndrome and adipocytokines
FEBS Letters 580 (2006) 2917 2921 Minireview The metabolic syndrome and adipocytokines Yuji Matsuzawa * Sumitomo Hospital, Professor Emeritus Osaka University, 5-3-20 Nakanoshima, Kita-Ku, Osaka 530-0005,
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationElevated Serum Levels of Adropin in Patients with Type 2 Diabetes Mellitus and its Association with
Elevated Serum Levels of Adropin in Patients with Type 2 Diabetes Mellitus and its Association with Insulin Resistance Mehrnoosh Shanaki, Ph.D. Assistant Professor of Clinical Biochemistry Shahid Beheshti
More information300 Biomed Environ Sci, 2018; 31(4):
300 Biomed Environ Sci, 2018; 31(4): 300-305 Letter to the Editor Combined Influence of Insulin Resistance and Inflammatory Biomarkers on Type 2 Diabetes: A Population-based Prospective Cohort Study of
More informationDecreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation
European Journal of Endocrinology (2003) 148 657 662 ISSN 0804-4643 CLINICAL STUDY Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation Miyao Matsubara, Katsuhiko
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationPage 1. Disclosures. Background. No disclosures
Population-Based Lipid Screening in the Era of a Childhood Obesity Epidemic: The Importance of Non-HDL Cholesterol Assessment Brian W. McCrindle, Cedric Manlhiot, Don Gibson, Nita Chahal, Helen Wong, Karen
More informationAssociation of serum adipose triglyceride lipase levels with obesity and diabetes
Association of serum adipose triglyceride lipase levels with obesity and diabetes L. Yang 1 *, S.J. Chen 1 *, G.Y. Yuan 1, L.B. Zhou 2, D. Wang 1, X.Z. Wang 1 and J.J. Chen 1 1 Department of Endocrinology,
More informationJournal of the American College of Cardiology Vol. 48, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.06.053
More informationSupplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
More informationPongamorn Bunnag, MD Boonsong Ongphiphadhanakul, MD. Mahidol University
Roles oesof Fetuin-A in Hypertension Pongamorn Bunnag, MD Boonsong Ongphiphadhanakul, MD Ramathibodi Hospital Mahidol University Fetuin-A (Alpha-2-HS-glycoprotein) Multi-functional protein secreted by
More informationCauses of death in Diabetes
Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationJMSCR Volume 03 Issue 04 Page April 2015
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x Study of Metabolic Syndrome and Thyroid Dysfunction Authors Dr. Nalini R Humaney, Dr. Saurabh Ashok Lande, Dr. Ramesh P Mundle N.K.P.Salve
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationASSeSSing the risk of fatal cardiovascular disease
ASSeSSing the risk of fatal cardiovascular disease «Systematic Cerebrovascular and coronary Risk Evaluation» think total vascular risk Assess the risk Set the targets Act to get to goal revised; aupril
More informationThe role of physical activity in the prevention and management of hypertension and obesity
The 1 st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) Berlin, October 26-29 2005 The role of physical activity in the prevention and management of hypertension and obesity
More informationObesity and Insulin Resistance According to Age in Newly Diagnosed Type 2 Diabetes Patients in Korea
https://doi.org/10.7180/kmj.2016.31.2.157 KMJ Original Article Obesity and Insulin Resistance According to Age in Newly Diagnosed Type 2 Diabetes Patients in Korea Ju Won Lee, Nam Kyu Kim, Hyun Joon Park,
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationORIGINAL ARTICLE SUMMARY
ORIGINAL ARTICLE HIP CIRCUMFERENCE IS AN IMPORTANT PREDICTOR OF PLASMA C-REACTIVE PROTEIN LEVELS IN OVERWEIGHT AND OBESE TAIWANESE WOMEN Hei-Jen Jou 1,2, I-Ping Hsu 3, Pei-Ying Ling 1, Chia-Tzu Lin 1,
More informationAssociation between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese
Diabetes Care Publish Ahead of Print, published online June 12, 2008 Raised Blood Pressure and Dysglycemia Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese Bernard My Cheung,
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationAUTONOMIC FUNCTION IS A HIGH PRIORITY
AUTONOMIC FUNCTION IS A HIGH PRIORITY 1 Bladder-Bowel-AD Tetraplegia Sexual function Walking Bladder-Bowel-AD Paraplegia Sexual function Walking 0 10 20 30 40 50 Percentage of respondents an ailment not
More informationRisk Assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication
41 Research Article Risk Assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication Amarjeet Singh*, Sudeep bhardwaj, Ashutosh aggarwal Department of Pharmacology, Seth
More informationHypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents
Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of
More informationThe Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health
More informationCardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009
Cardiovascular disease, studies at the cellular and molecular level Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009 Content Introduction The number 1 killer in America Some statistics
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationOBESITY IS COMMONLY associated with insulin resistance
0021-972X/01/$03.00/0 Vol. 86, No. 5 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close
More informationROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret
ROLE OF INFLAMMATION IN HYPERTENSION Dr Barasa FA Physician Cardiologist Eldoret Outline Inflammation in CVDs the evidence Basic Science in Cardiovascular inflammation: The Main players Inflammation as
More informationCRP and fibrinogen imply clinical outcome of patients with type-2 diabetes. and coronary artery disease
CRP and fibrinogen imply clinical outcome of patients with type-2 diabetes and coronary artery disease Marijan Bosevski 1, *, Golubinka Bosevska 1, Lily Stojanovska 2, Vasso Apostolopoulos 2, * 1 University
More informationImpact of Adiponectin on Left Ventricular Mass Index in Non-complicated Obese Subjects
Endocrine Journal 2008, 55 (3), 523 528 Impact of Adiponectin on Left Ventricular Mass Index in Non-complicated Obese Subjects HAKSUN EBİNÇ, FATMA AYERDEN EBİNÇ*, ZÜBEYDE NUR ÖZKURT**, MEHMET TOLGA DOĞRU,
More informationPlasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationPATIENTS AND METHODS:
BACKGROUND: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by erosive synovitis that involves peripheral joints and implicates an important influence in the quality
More informationKEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers
CardioMetabolic Risk Poor blood sugar regulation and unhealthy triglyceride and lipoprotein levels often present long before the diagnosis of type 2 Diabetes. SpectraCell s CardioMetabolic and Pre-Diabetes
More informationAtherosclerotic diseases are the leading cause of death in
Adiponectin and Metabolic Syndrome Yuji Matsuzawa, Tohru Funahashi, Shinji Kihara, Iichiro Shimomura Abstract In this review article, the crucial roles of adipocytes in the development of so-called metabolic
More informationObesity, defined as excess fat accumulation, is the most
Association of Hypoadiponectinemia With Coronary Artery Disease in Men Masahiro Kumada, Shinji Kihara, Satoru Sumitsuji, Toshiharu Kawamoto, Satoru Matsumoto, Noriyuki Ouchi, Yukio Arita, Yoshihisa Okamoto,
More informationCardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century November 2, 2016
Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century November 2, 2016 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process
More information902 Biomed Environ Sci, 2014; 27(11):
902 Biomed Environ Sci, 2014; 27(11): 902-906 Letter to the Editor Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type
More informationPrediction of Homeostasis Model Assessment of Insulin Resistance in Japanese Subjects
Tokai J Exp Clin Med., Vol. 37, No. 4, pp. 12-16, 212 Prediction of Homeostasis Model Assessment of Insulin Resistance in Japanese Subjects Masako NEGAMI, Eiko TAKAHASHI, Hiroki OTSUKA and Kengo MORIYAMA
More informationEffect of Fenofibrate on Adiponectin and Inflammatory Biomarkers in Metabolic Syndrome Patients
nature publishing group Effect of Fenofibrate on Adiponectin and Inflammatory Biomarkers in Metabolic Syndrome Patients Robert S. Rosenson 1 Adiponectin is an adipose-secreted hormone with anti-inflammatory
More informationAssociation of urine acidification with visceral obesity and the metabolic syndrome
Endocrine Journal 2011, 58 (5), 363-367 Or i g i n a l Association of urine acidification with visceral obesity and the metabolic syndrome Michio Otsuki 1), Tetsuhiro Kitamura 1), Kayoko Goya 3), Hiroshi
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationMetabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology
Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationDiabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome
Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome John E. Nestler, M.D. William Branch Porter Professor of Medicine Chair, Department of Internal Medicine Virginia Commonwealth University
More informationAnnals of RSCB Vol. XVI, Issue 1
THE STUDY OF PROTHROBOTIC STATE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASES Oana Bădulescu 1, Codruţa Bădescu 2, Manuela Ciocoiu 1, Magda Bădescu 1 1 DEPARTMENT OF PATHOPHYSIOLOGY;
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationAndrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University
CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationIndex. Note: Page numbers of article titles are in boldface type.
Heart Failure Clin 2 (2006) 101 105 Index Note: Page numbers of article titles are in boldface type. A ACE inhibitors, in diabetic hypertension, 30 31 Adipokines, cardiovascular events related to, 6 Advanced
More informationAdiponectin, TG/HDL-cholesterol index and hs-crp. Predictors of insulin resistance.
ORIGINAL ARTICLE Adiponectin, TG/HDL-cholesterol index and hs-crp. Predictors of insulin resistance. Bonneau GA y Pedrozo WR 1 Ministry of Public Health, Province of Misiones, 2 School of Exact, Chemical
More informationDecreased Serum Levels of Adiponectin Are a Risk Factor for the Progression to Type 2 Diabetes in the Japanese Population
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Decreased Serum Levels of Adiponectin Are a Risk Factor for the Progression to Type 2 Diabetes in the Japanese Population
More informationIs socioeconomic position related to the prevalence of metabolic syndrome? Influence of
Is socioeconomic position related to the prevalence of metabolic syndrome? Influence of social class across the life-course in a population-based study of older men Sheena E Ramsay, MPH 1, Peter H Whincup,
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationMethods. Background and Objectives STRADIVARIUS
STRADIVARIUS Effect of on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease Steven E. Nissen MD Stephen J. Nicholls MBBS PhD, Kathy Wolski MPH, Josep Rodés-Cabau
More informationSupplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms
Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±
More informationThe Impact Of Adiposity And Insulin Resistance On Endothelial Function In Middle-Aged Subjects
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 1 Number 1 The Impact Of Adiposity And Insulin Resistance On Endothelial Function In Middle-Aged Subjects L Zhu, K Liu Citation L Zhu, K
More informationCARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES
CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis
More informationManagement of Cardiovascular Disease in Diabetes
Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western
More informationObesity in the pathogenesis of chronic disease
Portoroz October 16th 2013 Obesity in the pathogenesis of chronic disease Rocco Barazzoni University of Trieste Department of Medical, Surgical and Health Sciences Obesity Trends* Among U.S. Adults BRFSS,
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationPlasma Adiponectin and Insulin Resistance in Korean Type 2 Diabetes Mellitus
Yonsei Medical Journal Vol. 46, No. 1, pp. 42-50, 2005 Plasma Adiponectin and Insulin Resistance in Korean Type 2 Diabetes Mellitus Mi-Jin Kim 1, Kwang-Ha Yoo 1, Hyung-Suk Park 1, Sang-Man Chung 1, Choon-Jo
More informationDiabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions
Diabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions Diabetes is one of the largest global health emergencies of 21 st century, with the number of people with
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationhttp://noodlemaz.wordpress.com/category/science/cancer/ Outline Introduction Serious nature of Cardiovascular Disease (CVD) How to prevent CVD? The disease process Damage and plaque development Current
More informationREAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING
REAGENTS RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING Randox sdldl Cholesterol (sdldl-c) Size Matters: The True Wight of Risk in Lipid Profiling 1. BACKGROUND
More informationHypoinsulinemia is strongly associated with coronary artery calcification (CAC) assessed by multislice computed tomography
Hypoinsulinemia is strongly associated with coronary artery calcification (CAC) assessed by multislice computed tomography Yohei Oda 1, Muhei Tanaka 2, Michiaki Fukui 2, Sei Tsunoda 1, Satoshi Akabame
More informationImpact of Body Mass Index and Metabolic Syndrome on the Characteristics of Coronary Plaques Using Computed Tomography Angiography
Impact of Body Mass Index and Metabolic Syndrome on the Characteristics of Coronary Plaques Using Computed Tomography Angiography Cardiovascular Division, Faculty of Medicine, University of Tsukuba Akira
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationTerm-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY
MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple
More informationEffects of Statins on Endothelial Function in Patients with Coronary Artery Disease
Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease Iana I. Simova, MD; Stefan V. Denchev, PhD; Simeon I. Dimitrov, PhD Clinic of Cardiology, University Hospital Alexandrovska,
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More information